Quantitative SPECT/CT Imaging of 177Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy

Molecular Imaging and Biology

Volumn 17, Issue 4, 2015, Pages 585-593

  Sanders, J C ^a,b   Kuwert, T ^b   Hornegger, J ^a   Ritt, P ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Dosimetry; Peptide receptor radionuclide therapy; Quantitative SPECT; 177Lu DOTATATE

Indexed keywords

LUTETIUM 177; PEPTIDE RECEPTOR; RECEPTOR; TETULOMAB TETRAXETAN LUTETIUM LU 177; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BLADDER; CALIBRATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FEMALE; HUMAN; IN VIVO STUDY; MALE; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHANTOM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOTHERAPY; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; URINALYSIS; VALIDATION STUDY; ALGORITHM; ANALOGS AND DERIVATIVES; CHEMISTRY; DIGESTIVE SYSTEM NEOPLASMS; IMAGING PHANTOM; METABOLISM; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROCEDURES; SCINTISCANNING; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PHANTOMS, IMAGING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER;

EID: 84937524772     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0806-4     Document Type: Article

References (35)

1. Stillebroer AB, Boerman OC, Desar IME et al (2013) Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol 64:478–485
2. Tagawa ST, Milowsky MI, Morris M et al (2013) Pase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 19:5182–5191
3. Chakraborty S, Das T, Banerjee S et al (2006) Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl Med Commun 27:661–668
4. 1]-octreotide. Ann N Y Acad Sci 733:496–506
5. de Jong M, Bakker WH, Breeman WAP et al (1998) Pre-clinical comparison of [DPTA0] octreotide, [DTPA0, Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 75:406–411
6. Valkema R, Pauwels S, Kvols LK et al (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147–156
7. Forrer F, Valkema R, Kwekkeboom DJ et al (2007) Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 21:111–129
8. Teunissen JJM, Kwekkeboom DJ, Valkema R et al (2011) Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 18:S27–S51
9. Kwekkeboom DJ, Bakker WH, Kooij PP et al (2001) [177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med Mol Imaging 28:1319–1325
10. de Jong M, Valkema R, Jamar F et al (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133–140
11. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 28:2124–2130
12. Khan S, Krenning EP, van Essen M et al (2011) Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Nucl Med 52:1361–1368
13. Watson EE, Stabin MG, Siegel JA (1993) MIRD formulation. Med Phys 20:511–514
14. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med 31(9):1257–1262
15. Ritt P, Vija H, Hornegger J, Kuwert T (2011) Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging 38:S69–S77
16. Willowson K, Bailey DL, Baldock C (2008) Quantitative SPECT reconstruction using CT-derived corrections. Phys Med Biol 53:3099–3112
17. Bailey DL, Willowson KP (2014) Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality. Eur J Nucl Med Mol Imaging 41:S17–S25
18. 3-octreotate. Eur J Nucl Med Mol Imaging 37:212–225
19. Ichihara T, Ogawa K, Motomura N et al (1993) Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med 34:2216–2221
20. de Nijs R, Lagerburg V, Klausen TL, Holm S (2014) Improving quantitative dosimetry in 177Lu-DOTATATE SPECT by energy window-based scatter corrections. Nucl Med Commun 35:522–533
21. Vija AH, Hawman EG, Engdahl JC (2003) Analysis of a SPECT OSEM reconstruction method with 3D beam modeling and optional attenuation correction: phantom studies. IEEE Nucl Sci Symp Med Imaging Conf Rec 4:2662–2666
22. 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J Nucl Med 51:921–928
23. 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging 11:56–66
24. Hudson HM, Larkin RS (1994) Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 13:601–609
25. Dewaraja YK, Frey EC, Sgouros G et al (2012) MIRD Pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med 53:1310–1325
26. Chun SY, Fessler JA, Dewaraja YK (2013) Post-reconstruction non-local means filtering methods using CT side information for quantitative SPECT. Phys Med Biol 58:6225–6240
27. Tsui BMW, Zhao XD, Frey EC (1991) Comparison between ML-EM and WLS-CG algorithms for SPECT image reconstruction. IEEE Trans Nucl Sci 38:1766–1772
28. 188Re. Appl Radiat Isot 55:89–96
29. Hutton BF, Hudson HM, Beekman FJ (1997) A clinical perspective of accelerated statistical reconstruction. Eur J Nucl Med Mol Imaging 24:797–808
30. 90Y targeted radionuclide therapies. Phys Med Biol 57:5733–5747
31. Sorenson JA (1975) Deadtime characteristics of Anger cameras. J Nucl Med 16:284–288
32. Frey EC, Tsui BMW (1996) A new method for modeling the spatially-variant, object-dependent scatter response function in SPECT. IEEE Nucl Sci Symp Med Imaging Conf Rec 2:1082–1086
33. Fessler JA, Rogers WL (1996) Spatial resolution properties of penalized-likelihood image reconstruction: space-invariant tomographs. IEEE Trans Image Proc 5:1346–1358
34. Liow JS, Strother SC (1993) The convergence of object dependent resolution in maximum likelihood based tomographic image reconstruction. Phys Med Biol 38:55–70
35. Maus J, Hofheinz F, Schramm G et al (2014) Evaluation of PET quantification accuracy in vivo. Nuklearmedizin 53:67–77